5 September 2024 Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis.
GSK today announced positive headline results of MATINEE, the Phase III clinical trial evaluating its asthma drug Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD). 6 September 2024
Organon KK, a Japan subsidiary of Organon & Co, announced that the primary endpoint was achieved in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A 6 September 2024
The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). 6 September 2024
Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, today announced a research collaboration with US pharma major Eli Lilly to develop genetic medicine therapeutics. 6 September 2024
The short-acting insulin market is poised for significant growth, driven by a rising prevalence of diabetes, technological advancements, and evolving healthcare policies. 6 September 2024
San Diego, USA-based Travere Therapeutics saw its shares close up more than 8% at $10.75 yesterday on positive news form the US regulator. 6 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
In an interview with Danish national public radio broadcast station DR, Henrik Juuel, chief financial officer of vaccine maker Bavarian Nordic, reacted to public calls for the company to lower the price of its mpox vaccine. 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Voyager Therapeutics (Nasdaq: VYGR) has entered into a new licensing agreement with Novartis (NOVN: VX), building on a partnership that began in March 2022. 6 September 2024
The Biosimilars Council, alongside the Association for Accessible Medicines (AAM), released its 2024 US Generic & Biosimilar Medicines Savings Report. 6 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Shares of US gamma-delta T cell therapies for cancer developer IN8bio closed down more than 7% yesterday and fell a further 3.2% to $0.465 pre-market, after it announced a major reshuffle. 5 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Gene therapy company Genprex (Nasdaq: GNPX) has announced plans to transfer its diabetes program and related assets into a new, wholly-owned subsidiary. 5 September 2024
Glenmark Pharmaceuticals has agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the US Department of Justice announced. 5 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Recursion (Nasdaq: RXRX) has seen its shares fall by more than 15% following the announcement of Phase II trial results for REC-994, an investigational treatment for symptomatic cerebral cavernous malformation (CCM). 4 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
A series of key leadership changes have been announced on Tuesday at Dyne Therapeutics, a muscle disease company developing therapeutics for people living with genetically-driven diseases. 3 September 2024
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
UK-based Amphista Therapeutics—which calls itself a leader in next generation targeted protein degradation (TPD) approaches—has named Antony Mattessich its new chief executive (CEO) and member of the board of directors. 3 September 2024
Industry analysts forecast that North America is expected to lead the global cancer monoclonal antibodies market in the coming years, driven by an increasing incidence of cancer and favorable regulatory developments. 3 September 2024
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
California, USA-based vaccine developer Vaxcyte saw its shares leap almost 33% to $107.12 in pre-market activity as it revealed very impressive early-stage trial results. 3 September 2024
EC approved Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for urothelial carcinoma in adults. 3 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized mRNA specialist Moderna’s updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2. 3 September 2024
Anthos Therapeutics has reported a new analysis from the landmark AZALEA-TIMI 71 study, demonstrated that the investigational Factor XI inhibitor abelacimab was associated with remarkably low levels of periprocedural bleeding in patients with atrial fibrillation (AFib). 3 September 2024
Germany’s Bayer (BAYN: DE) has presented detailed results from its Phase III OCEANIC-AF trial for the blood thinner asundexian at the annual meeting of the European Society of Cardiology (ESC). 3 September 2024
The market for anaplastic lymphoma kinase (ALK) inhibitors is projected to expand in the coming years, fueled by an increasing number of cancer diagnoses and heightened awareness of these therapies. 2 September 2024